FITC Anti-Human CD134 Antibody[ Ber-ACT35]

The FITC Anti-Human CD134 Antibody [BER-ACT35] is a highly specific and reliable tool designed for the detection and analysis of CD134 expression in human samples. This antibody is conjugated with fluorescein isothiocyanate (FITC), a widely used fluorochrome known for its exceptional brightness and stability, ensuring accurate and consistent results.

CD134, also known as OX40, is a cell surface receptor belonging to the tumor necrosis factor receptor superfamily. It is primarily expressed on activated T cells, including CD4+ and CD8+ T cells, as well as regulatory T cells. CD134 plays a crucial role in T cell activation, survival, and proliferation, making it an essential target for immunological research and diagnostic applications.

The FITC Anti-Human CD134 Antibody [BER-ACT35] has been extensively validated for its specificity and sensitivity in various experimental settings, including flow cytometry, immunohistochemistry, and immunofluorescence. It exhibits minimal cross-reactivity with other cell surface markers, ensuring accurate identification and quantification of CD134-positive cells.

This antibody offers exceptional performance characteristics, including high signal-to-noise ratio, low background staining, and excellent reproducibility. Its bright fluorescence allows for easy visualization and enumeration of CD134-expressing cells, facilitating precise analysis and interpretation of experimental data.

The FITC Anti-Human CD134 Antibody [BER-ACT35] is supplied in a convenient and ready-to-use format, eliminating the need for time-consuming and error-prone conjugation procedures. It is provided in a liquid formulation, ensuring optimal stability and long shelf life.

In summary, the FITC Anti-Human CD134 Antibody [BER-ACT35] is a reliable and high-quality reagent that enables accurate detection and analysis of CD134 expression in human samples. Its exceptional performance characteristics and ease of use make it an invaluable tool for researchers and clinicians in the fields of immunology, oncology, and autoimmune diseases.